Keith Meadors Joins Precipio to Lead its Products Division
June 13, 2022 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice...
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
May 24, 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale of its...
Precipio Signs First IV-Cell Customer Agreement
May 10, 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida,...
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
April 26, 2022 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call
March 22, 2022 18:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2021 and year end shareholder update call on Monday,...
Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO
March 21, 2022 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Mr. Carl Iberger, Precipio’s CFO for the past five...
Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022
February 24, 2022 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced its unaudited and preliminary results for 2021. The Company...
New York State Approves Precipio’s HemeScreen for POL clinical use
November 18, 2021 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...
Precipio Announces Q3-2021 and year-end Shareholder Update Call
November 01, 2021 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2021 update call on Monday, November 15th at 5:00 PM...
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory
August 26, 2021 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth...